Here, we briefly discuss the role ofGLP-1in normal energy intake and reward and then review the emerging evidence suggesting that disruptions toGLP-1signaling are associated withbingeeating. We also consider the potential utility ofGLP-1-based pharmacotherapies for reducingbingeeatingbehavior.
Small pilot studies showGLP-1RAs like liraglutide reducebingeeating, body weight, and comorbidities inbingeeatingdisorder and bulimia nervosa.GLP-1RAs have favorable psychiatric side effect profile compared to current medical treatments. ...
Sep 3, 2025 ·The landscape of nutrition and health has entered a new frontier. Although public attention focuses on the weight-loss results of glucagon-like peptide-1(GLP-1) medications like Wegovy® and Mounjaro®, these interventions are showcasingprecisionnutrition as a mainstream approach to health and wellness.
This particular example perfectly highlights why Glp-1 Therapy For Binge Eating In Precision Hyperactivity is so captivating.
Jan 15, 2025 ·Here we provide a targeted synthesis of recent developments in the field ofGLP-1neurobiology, highlighting studies which have advanced our understanding of howGLP-1signaling modulateseating, and identify open questions and future challenges we believe still need to be addressed to aid the prevention and/or treatment of obesity.
Nov 13, 2025 ·Bingeeatingdisorder (BED) is a prevalenteatingdisorder lacking adequate pharmacological interventions. This review examines the therapeutic potential of glucagon-like peptide-1receptor agonists (GLP-1RAs), medications approved for type 2 diabetes and obesity now being investigated foreatingdisorders through their modulation of metabolic and reward pathways. A narrative review was ...
